In clinical trials against tuberculosis, SQ-109 was administered orally at doses 75-300 mg daily

MIC assays were performed in 96-well round-bottom plates for seven-days. SQ-109 was suspended in DMSO at a final concentration of 10 mM and diluted 100-fold into 7H9-OADC liquid medium containing 0.05% Tween-80. This 100 uM stock was diluted by 2-fold serial dilutions in the same medium in microtiter wells, resulting in 50 uL total volume in each well. In addition to a control lacking drug, the lowest concentration of drug assayed was 0.04 uM (11 dilutions total). M. tuberculosis H37Rv was grown to an optical density [600nm] 0.5 and diluted 1:10 before adding 50 uL to each individual well of the 96-well plates. The final optical density at 600nm was 0.025, and there was no visible growth within the wells of the microtiter plate. Upon incubation for 7 days at 37 °C, growth became apparent, and the MIC was determined to be the lowest concentration that prevents visible growth. MIC for SQ-109 in this assay was 0.2 uM.